News | August 01, 2025
Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Upgrades 2025 full-year CDMO sales and margin outlook
Combined strength of two brands across 11 states to elevate patient care delivery and access to doctors
Subscribe To Our Newsletter & Stay Updated
